Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month High – What’s Next?

Royalty Pharma PLC (NASDAQ:RPRX)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $51.72 and last traded at $51.6360, with a volume of 2026665 shares. The stock had previously closed at $50.79.

Wall Street Analysts Forecast Growth

RPRX has been the topic of several analyst reports. The Goldman Sachs Group reissued a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Morgan Stanley boosted their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. JPMorgan Chase & Co. boosted their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, May 1st. Finally, Citigroup boosted their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $53.71.

Royalty Pharma Stock Up 1.7%

The company has a market capitalization of $29.79 billion, a price-to-earnings ratio of 35.14, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The firm’s 50 day moving average price is $47.62 and its two-hundred day moving average price is $42.75. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. The company had revenue of $631.00 million for the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. Sell-side analysts anticipate that Royalty Pharma PLC will post 5.04 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.8%. Royalty Pharma’s payout ratio is currently 63.95%.

Insider Buying and Selling at Royalty Pharma

In other news, CFO Terrance P. Coyne sold 34,791 shares of the business’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 139,164 shares of company stock worth $6,624,902. 18.84% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its stake in Royalty Pharma by 367.7% in the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after buying an additional 160,191 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Royalty Pharma by 20.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock valued at $2,490,000 after buying an additional 13,489 shares during the last quarter. Focus Partners Wealth acquired a new position in Royalty Pharma in the 1st quarter valued at about $264,000. Intech Investment Management LLC grew its stake in Royalty Pharma by 41.0% in the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock valued at $1,494,000 after buying an additional 13,951 shares during the last quarter. Finally, Invesco Ltd. grew its stake in Royalty Pharma by 21.4% in the 2nd quarter. Invesco Ltd. now owns 1,559,378 shares of the biopharmaceutical company’s stock valued at $56,184,000 after buying an additional 274,960 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.